Morgan Stanley: Illumina's Q1 Guidance Puts 2019 Targets In Question

Illumina, Inc. ILMN announced 2019 revenue growth guidance of 13-14 percent, and much of this revenue growth is expected to be in the back half of the year.

Yet the company's first-quarter guidance raises concerns around whether Illumina can meet its full-year target, according to Morgan Stanley.

The Analyst

Analyst Steve Beuchaw maintains an Equal-Weight rating on Illumina with a $288 price target. 

The Thesis

Illumina reported a marked deceleration in revenue growth to 11 percent in Q4 versus the 20-percent growth generated in the previous four quarters, Beuchaw said in a Wednesday note.

The Q4 results were pre-announced and the 2019 guidance was as expected, the analyst said. 

Illumina’s Q1 guidance grabbed attention, as it reflects a deceleration in growth to single digits and is 6-percent below consensus expectations, Beuchaw said. Investor feedback “highlights a lack of confidence” in the company being able to achieve its 2019 guidance, he said. 

The 2019 guidance indicates large population sequencing projects that will impact near-term results, the analyst said. 

Morgan Stanley lowered its revenue estimates for 2019 and 2020 by 6.7 percent and 8 percent, respectively. The firm also lowered margin expansion expectations, resulting in a downward revision of EPS estimates for 2019 and 2020 from $6.83 to $6.38 and from $8.28 to $7.69, respectively.

Price Action

Illumina shares were down 4.86 percent at $271.39 at the time of publication Wednesday. 

Related Links:

The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance

Earnings Scheduled For January 29, 2019

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsGuidancePrice TargetReiterationAnalyst RatingsMorgan StanleySteve Beuchaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!